Astrazeneca is one of the world’s leading drugs companies with a growing pipeline of cancer treatments STEFAN WERMUTH/REUTERSA new partnership has been launched between Astrazeneca and Cancer Research UK to harness big data and genetics and accelerate the development of new medicines. The Anglo-Swedish pharmaceuticals company and the charity are collaborating on a new centre of excellence based in the Milner Therapeutics Institute at the University of Cambridge. Astrazeneca, which is also building a new headquarters in the city, is one of the world’s leading drugs companies with a filling pipeline of cancer treatments. Sales of its oncology products jumped by 42 per cent to almost $2.7 billion in the first half of its financial year. The FTSE 100 group hopes that the functional genomics centre will develop technology to “better understand the biology of cancer” and that it will advance “computational…

Source: The Times December 11, 2018 03:55 UTC